Brainsway Closes Gap Between Devices And Drugs With Noninvasive Deep Brain Stimulation

Deep brain stimulation technologies continue to gather momentum. Following a series of private investments and strategic acquisitions, Brainsway Ltd. announced in early July that it had received CE mark approval for a new therapy for chronic neuropathic pain, bringing another potential neurostimulation treatment to market in Europe. Meanwhile, the company reported positive interim results on its clinical trial of a treatment for obsessive compulsive disorder, adding to positive results from a pivotal multicenter trial studying its therapy for major depression. These trials validate a new device therapy for conditions that neurologists and psychiatrists typically treat with drugs.